Vivos Inc Summarizes Progress in its Animal Therapy Division
MWN-AI** Summary
Vivos Inc. (OTCQB: RDGL) has reported a remarkable year for its IsoPet division, achieving a staggering 1,200% year-over-year increase in administered therapies from 2024 to 2025. This surge reflects a significant shift in veterinary adoption as a growing number of pet owners and veterinarians seek IsoPet therapy, a cost-effective and precise alternative to traditional radiation. The company anticipates accelerating demand as it expands its network of certified clinics, which now totals 17 following the recent certifications of the Sun City Veterinary Surgery Center in Texas and the University of Florida Small Animal Hospital.
The IsoPet division's progress includes the safe administration of over 100 therapies across various animal species, including dogs, cats, horses, and exotic pets. Capital Veterinary Specialists in Tallahassee is providing subsidized IsoPet treatments and is set to publish a case study on clinical outcomes after treating 30 patients in late 2025, marking a high point for the service.
In an effort to enhance profitability, the division will implement efficiency-focused strategies starting in Q1 2026, alongside expanding therapeutic offerings. Vivos also highlights its partnership with Exubrion Therapeutics to target the high-growth equine oncology segment, reporting successful treatments for equine ocular squamous cell carcinoma without ocular damage. The success of its subsidized therapies that generate valuable clinical data will further support marketing efforts aimed at veterinarians and oncologists.
With the IsoPet website revamped for better user experience and ongoing clinical studies to further establish the effectiveness of its treatments, Vivos Inc. is positioned for continued growth in veterinary oncology through 2026 and beyond.
MWN-AI** Analysis
Vivos Inc. (OTCQB: RDGL) has made significant strides in its IsoPet division, reporting a remarkable 1,200% year-over-year increase in therapies administered from 2024 to 2025. This uptick reflects growing awareness and acceptance of IsoPet therapy as a viable alternative to traditional treatments for pet oncology, supported by rising inquiries from veterinarians and pet owners alike.
As we head into 2026, Vivos is poised to implement profitability-focused initiatives, capitalizing on the surge in demand. By expanding its network of certified clinics—which already totals 17, including new certifications at institutions like the University of Florida—Vivos significantly broadens its market outreach. The collaboration with the Capital Veterinary Specialists to deliver subsidized treatments and generate clinical data further enhances its credibility and positions IsoPet as a sought-after treatment option.
The four key growth strategies for Vivos include advancing its clinical outreach, expanding educational resources for veterinarians, and leveraging data from case studies to drive adoption of IsoPet therapy. Launching a newly designed website in partnership with Exubrion will also improve user experience and awareness, allowing both pet owners and veterinarians to access comprehensive information easily.
The growing market for precision oncology treatments in both small and large animals presents a lucrative opportunity for growth, particularly with a thriving equine oncology segment. Moreover, the company's strategic partnership with Exubrion Therapeutics positions it favorably in the regenerative medicine arena, further enhancing potential revenue streams.
Given the current trajectory and subsequent advancements in 2026, investors may find potential in Vivos Inc.'s stock, particularly if they demonstrate sustained growth and profitability. Monitoring clinical outcomes, expanded market reach, and effective marketing will be crucial in evaluating the company’s performance over the next year. Engaging with developments closely will provide insights into timely investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Kennewick, WA, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The IsoPet division reported a 1,200% year-over-year increase in administered therapies from 2024 to 2025, reflecting accelerating veterinary adoption nationwide. In recent months, the Company has seen a sharp rise in inbound inquiries from both veterinarians and pet owners seeking access to IsoPet therapy, signaling growing awareness and demand for this precise, cost-effective alternative to traditional radiation. Starting in Q1 2026, the division will implement profitability-focused initiatives while continuing to expand its network of certified clinics.
Over 100 IsoPet treatments have been safely performed across dogs, cats, horses, and exotic animals.
Capital Veterinary Specialists (Tallahassee, FL) is administering IsoPet at a subsidized rate for microscopic disease following tumor resection and will publish a case study on clinical outcomes.
- Seventeen patients were treated in November and thirteen patients in December, for an all-time high.
- 2025 has been a turning point for our IsoPet Division. We have been able to scale our pet patients treated (1,200% growth YoY) and production output. We are also continuously improving our internal processes to become more efficient, as we look for continued growth in 2026.
- Case study therapies are now 100% completed. We anticipate 2026 will result in multiple publications, which will help with marketing to the veterinarians and oncologists that require more data before offering Isopet as a treatment. The highly cost-effective strategy of providing subsidized therapies to generate comprehensive clinical data has yielded valuable results. After completing these studies in 2026 these therapies will begin generating revenue.
- As a result of our partnership with Exubrion, the new IsoPet website offers a cleaner, more informative experience for pet owners and clinicians, and it showcases the work of PixelRank, now our shared web designer.
- Two new clinics have been certified, Sun City and the University of Florida, bringing the total clinic count to 17 by the end of 2025 with more interested clinics in the pipeline for 2026.
1. Sun City Veterinary Surgery Center in El Paso, Texas, has been certified to offer IsoPet® Precision Radionuclide Therapy™ for small animals.
This certification marks the first companion animal hospital in Texas approved to provide IsoPet® therapy and complements an equine certified IsoPet® clinic, Brazos Valley Equine Hospital in Navasota, Texas, expanding IsoPet® availability across both companion animal and equine patients in the state of Texas.
Sun City Veterinary Surgery Center is a referral-only specialty practice led by Dr. Edward B. Silverman, DVM, MBA, MS, DACVS (SA), a board-certified small animal surgeon. Certification enables the practice to offer IsoPet® therapy to companion animals diagnosed with cancer, expanding access to advanced, targeted cancer treatment for pets in West Texas, Southern New Mexico and beyond.
“Establishing our first companion animal IsoPet® site in Texas is an important milestone for Vivos,” said Dr. Michael Korenko, CEO of Vivos Inc. “With equine treatment already available at Brazos Valley Equine Hospital and now companion animal care offered at Sun City Veterinary Surgery Center, we are building a broader veterinary footprint for IsoPet® therapy in the region.”
2. The University of Florida Small Animal Hospital has been certified to offer IsoPet® Precision Radionuclide Therapy™, expanding IsoPet availability at the University of Florida to include both small animal and equine large animal patients.
With this certification, IsoPet therapy is now available at both the University of Florida Small Animal Hospital and the University of Florida Large Animal Hospital (Equine), making UF one of the few academic veterinary centers equipped to deliver IsoPet across companion animal and equine oncology programs.
“The addition of the UF Small Animal Hospital strengthens an already outstanding veterinary oncology program,” said Dr. Michael Korenko, CEO of Vivos Inc. “Having both small animal and equine hospitals certified at the same institution reflects the University of Florida’s commitment to advancing cancer care across species and expanding access to innovative treatment options.”
The Company recently announced a strategic partnership with Exubrion Therapeutics, a leader in canine regenerative medicine, to co-market IsoPet in the high-value equine oncology segment. The equine segment represents a high-growth opportunity, with five certified clinics now operational, including Brazos Valley Equine Hospital. Four equine ocular squamous cell carcinoma cases were successfully treated without ocular damage, and a clinical publication is in development with Dr. Ben Buchanan.
Mike Korenko, ScD Brad Weeks, BA, MBA
CEO Vivos Inc President Vivos Inc
Michal.korenko@vivosinc.com Brad.Weeks@vivosinc.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.
FAQ**
How does Vivos Inc. (RDGL) plan to sustain the impressive 1,200% year-over-year growth in administered therapies into 2026, and what strategies are in place to expand awareness and adoption of IsoPet therapy among veterinarians?
What specific profitability-focused initiatives will Vivos Inc. (RDGL) implement in Q1 20to capitalize on the increasing demand for IsoPet therapy, and how will these initiatives impact the operational efficiency?
With the recent certifications of the Sun City Veterinary Surgery Center and the University of Florida, how does Vivos Inc. (RDGL) envision further expanding its network of certified clinics in 2026, especially in untapped regions?
Can Vivos Inc. (RDGL) provide details on the anticipated clinical publications in 2026 that will support marketing efforts for IsoPet therapy, and how will these studies help address veterinarian concerns regarding the treatment's efficacy?
**MWN-AI FAQ is based on asking OpenAI questions about Vivos Inc (OTC: RDGL).
NASDAQ: RDGL
RDGL Trading
1.28% G/L:
$0.079 Last:
175,652 Volume:
$0.0779 Open:
